NextCure Announces Closing of Public Offering
November 19 2019 - 4:05PM
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical
company committed to discovering and developing novel,
first-in-class immunomedicines to treat cancer and other
immune-related diseases, today announced the closing of its public
offering of 4,077,192 shares of its common stock at a public
offering price of $36.75 per share. The gross proceeds from the
offering, before deducting underwriting discounts and commissions
and estimated offering expenses, were approximately $150 million.
NextCure’s common stock is listed on The Nasdaq Global Select
Market under the ticker symbol “NXTC.”
Morgan Stanley, BofA Securities and Piper Jaffray & Co.
acted as joint book-running managers for the offering. Needham
& Company and BTIG acted as co-managers for the offering.
A registration statement relating to the shares sold in the
offering was declared effective by the Securities and Exchange
Commission (SEC) on November 14, 2019. This offering was made only
by means of a prospectus. Copies of the final prospectus relating
to this offering may be obtained by visiting EDGAR on the SEC’s
website at www.sec.gov or from: Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, New York 10014; BofA Securities, NC1-004-03-43, 200 North
College Street, 3rd floor, Charlotte, North Carolina 28255-0001,
Attn: Prospectus Department, or by email at
dg.prospectus_requests@bofa.com; Piper Jaffray & Co., 800
Nicollet Mall, J12S03, Minneapolis, Minnesota, 55402, Attention:
Prospectus Department, by telephone at (800) 747-3924 or by email
at prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or other jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About NextCure, Inc.NextCure is a
clinical-stage biopharmaceutical company committed to discovering
and developing novel, first-in-class immunomedicines to treat
cancer and other immune-related diseases.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
Media Inquiries
Shai Biran, Ph.D.
MacDougall
(781) 235-3060
sbiran@macbiocom.com
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From Apr 2023 to Apr 2024